An injectable hydrogel can mitigate damage to the right ventricle of the heart with chronic pressure overload, according to a new study. In 2019, this same hydrogel was shown to be safe in humans through an FDA-approved Phase 1 trial in people who suffered a heart attack. As a result of the new preclinical study, the FDA approved an investigational new drug application to start a clinical trial with the hydrogel in pediatric patients in the coming months, once institutional approvals are received.